Systemic sclerosis is, as the name defines, a thickening of the tissues in the skin. And it's also involving multiple organs in the body, not just the skin. And one of these is the lungs, so there ...

The drug is also approved to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), and other chronic interstitial lung diseases. In 2023, Boehringer tried to expand its label ...

Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The company also started a phase 2 trial in SSc-ILD shortly afterwards, saying that PRA023 had the potential to be a “pipeline in a product”. Meanwhile, following after PRA023 is PRA052 ...

The German pharma said it had filed dossiers with the FDA and the European Medicines Agency (EMA) for nintedanib, for interstitial lung disease associated with systemic sclerosis (SSc-ILD).

A new study from Thailand shows that a rapid peak in skin thickness progression in systemic sclerosis patients may predict ...